Medicofarma Biotech SA
WSE:MDB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.377
1.225
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medicofarma Biotech SA
Cash & Cash Equivalents
Medicofarma Biotech SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Cash & Cash Equivalents
zł507.6k
|
CAGR 3-Years
194%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Cash & Cash Equivalents
zł294k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Cash & Cash Equivalents
zł176.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
15%
|
CAGR 10-Years
41%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Cash & Cash Equivalents
zł14.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Medicofarma Biotech SA
Glance View
Medicofarma Biotech SA is a biotechnology company, which focuses on the innovative medicine, medicinal products, and biotechnology products. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2008-11-27. The company is engaged in works on drugs, medical devices and biotechnological products. It's research and development works are carried out in laboratories in Lublin and Poznan.
See Also
What is Medicofarma Biotech SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
507.6k
PLN
Based on the financial report for Dec 31, 2023, Medicofarma Biotech SA's Cash & Cash Equivalents amounts to 507.6k PLN.
What is Medicofarma Biotech SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
8%
Over the last year, the Cash & Cash Equivalents growth was 0%. The average annual Cash & Cash Equivalents growth rates for Medicofarma Biotech SA have been 194% over the past three years , 8% over the past five years .
You don't have any saved screeners yet
